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everity of Left Ventricular Remodeling Defines
utcomes and Response to Therapy in Heart Failure
alsartan Heart Failure Trial (Val-HeFT) Echocardiographic Data
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OBJECTIVES The objective of this study was to test the hypothesis that the severity of left ventricular
remodeling predicts the response to treatment and outcomes in chronic heart failure.
BACKGROUND Reversal of remodeling should produce the most favorable outcome in patients with the most
severe remodeling.
METHODS In 5,010 heart failure patients on background therapy and randomized to valsartan and
placebo, serial recordings of left ventricular internal diastolic diameter (LVIDd) and ejection
fraction (EF) were read at sites that had to meet qualifying standards before participating.
Baseline LVIDd and EF were pooled across treatments and retrospectively grouped by
quartiles Q1 to Q4, representing best to worst. Kaplan-Meier survival curves were obtained
by the log-rank test. Q1 was compared with Q4 for mortality and combined mortality and
morbidity (M M) from Cox regression risk ratios (RRs). Valsartan versus placebo changes
from baseline in LVIDd and EF were analyzed by quartiles from analysis of covariance.
Valsartan and placebo were compared by RRs for M  M.
RESULTS Survival rates were greater in the better quartiles for LVIDd and EF (p 0.00001). The RR for
Q1 versus Q4 in events approached 0.5 for both LVIDd and EF (p  0.0001). An LVIDd
decrease and EF increase were quartile-dependent and greater with valsartan than placebo at
virtually all time points. The RR for M  M outcomes favored valsartan in the worse quartiles.
CONCLUSIONS Stratification by baseline severity of remodeling showed that patients with worse LVIDd and
EF are at highest risk for an event, yet appear to gain the most anti-remodeling effect and
clinical benefit with valsartan treatment. (J Am Coll Cardiol 2004;43:2022–7) © 2004 by
the American College of Cardiology Foundationc
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dlinical trials in heart failure (HF) establish entry criteria that
nsure the severity of disease sufficient to detect a favorable
ffect of therapy on a mortality or morbidity end point. Left
entricular (LV) ejection fraction (EF), a marker for the extent
f functional and structural abnormalities of the ventricle, has
een identified as a guide to the risk of death and morbid
vents (1,2). Therefore, most HF trials have set a low EF as an
ntrance criterion, and in previous trials, the severity of a low
F has served as a guide to the risk of adverse events.
Therapy aimed at reversing or slowing the progression of
V remodeling would be expected to exert the most favorable
ffect in patients with the greatest severity of remodeling.
owever, in most previous trials, the sample size of the
chocardiographic data was inadequate to evaluate the relation-
hip between remodeling and outcome in individual patients.
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mployed by Novartis Pharmaceuticals Corp.
Manuscript received July 31, 2003; revised manuscript received December 1, 2003,
wccepted December 15, 2003.The Valsartan Heart Failure Trial (Val-HeFT) was
arried out in over 5,000 patients with HF, all of whom had
ore laboratory-monitored echocardiography performed at
aseline and during follow-up after randomization to val-
artan or placebo, in addition to all background HF therapy
3). Because the entrance criteria included both a low EF
40%) and a dilated ventricle (left ventricular internal
iastolic diameter [LVIDd]2.9 cm/m2 body surface area),
ll patients recruited into the trial had confirmed remodel-
ng of the LV. Valsartan treatment in the overall population
ed to a 13.2% reduction in combined mortality and mor-
idity (M  M) and an improvement in remodeling of the
V (4,5). The large sample size allowed us to further
xamine the extent to which the degree of remodeling
ontributed to outcomes and the response to valsartan (6).
ETHODS
chocardiography, both the recording and interpretation,
as carried out at 291 multi-national sites. Participation in
he trial was dependent on meeting specific core laboratory
tandards for recording and reading of LVIDd from two-
imensionally directed M-mode echocardiography, and EF
as derived from LV volumes using the area-length
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June 2, 2004:2022–7 Stratification of LV Remodeling and Outcomesethod. Total study reproducibility determined from du-
licate echocardiograms showed detectable treatment dif-
erences for LVIDd and EF, with a power of 90% and alpha
evel of 5%. During the trial, quality control was monitored
rom random sampling of patient studies, and this was
atisfactorily maintained (6).
Serial echocardiograms in 5,010 patients were obtained at
aseline before randomization and at 4, 12, 18, 24, and 30
onths after randomization. Baseline measurements of
VIDd and EF for the pooled population of valsartan and
lacebo patients were retrospectively grouped according to
uartiles Q1 to Q4, defined by increasing severity from best
o worst. Kaplan-Meier survival curves were constructed to
ompare baseline quartiles for LVIDd and EF. Differences
mong quartiles were assessed by the log-rank test. Cox
roportional hazard analysis was performed to investigate
he relation between the two primary study end points and
igure 1. Kaplan-Meier survival curves by baseline quartiles of left ventricu
alsartan and placebo data acquired over an average of 23 months of obs
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANCOVA  analysis of covariance
BB  beta-blocker
EF  ejection fraction
HF  heart failure
LV  left ventricle/ventricular
LVIDd  left ventricular internal diastolic diameter
M  M  combined mortality and morbidity
RR  risk ratio
Val-HeFT  Valsartan Heart Failure Trial.00001 by the log-rank test).aseline quartiles for LVIDd and EF. Cox regression risk
atios (RRs), comparing Q1 with Q4 for mortality (time to
eath) and for M M (time to death or first morbid event:
udden death with resuscitation, intravenous inotropic or
asodilator therapy, or hospitalization for HF), were calcu-
ated from pooled patient data. The treatment effects with
alsartan were also analyzed within the baseline quartiles.
nter-treatment differences in change from baseline in
VIDd and EF at months 4, 12, and 24 and end point by
uartiles of LVIDd and EF were based on least-squares
ean values by analysis of covariance (ANCOVA), which
ere adjusted for differences among patients with respect to
ther effects in the ANCOVA model. In addition to
reatment, the ANCOVA model included effects for base-
ine, continent, angiotensin-converting enzyme (ACE) in-
ibitor use, beta-blocker (BB) use, and treatment-by-
aseline interaction. Separate analyses were performed for
ach quartile and time point using this model. For each time
oint, the consistency of treatment differences across quar-
iles was assessed in an analysis of all quartile data by adding
reatment-by-quartile interaction (and quartile) effects to
he ANCOVA model already described. Risk ratios and
5% confidence intervals comparing valsartan with placebo
or M  M were calculated separately for each LVIDd and
F quartile, using Cox regression analysis, including adjust-
ent for New York Heart Association (NYHA) functional
lass, baseline ACE inhibitor and BB co-therapy, etiology,
nd age group; these were summarized graphically.
reatment-by-quartile interaction was assessed in a separate
ternal diastolic diameter (LVIDd) and ejection fraction (EF) from pooled
on after randomization. Differences among quartiles are significant (p lar in
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Stratification of LV Remodeling and Outcomes June 2, 2004:2022–7nalysis by incorporating the effects for treatment-by-
uartile interaction with those for treatment and LVIDd
nd EF quartiles. In addition, the odds of an event during
he trial for high (median) versus low LVIDd were
ompared across high (median) and low EF categories,
sing the Breslow-Day test for homogeneity of odds ratios.
his comparison was made for mortality and MM, based
n pooled patient data.
ESULTS
n this symptomatic population of patients in NYHA
unctional class II to IV, baseline quartiles of LVIDd from
he pooled (valsartan and placebo) population ranged from
arginal dilation of 6.3 cm to gross dilation of 7.5 cm.
aseline quartiles of EF ranged from a high of 32% to a
ow of22% (Fig. 1). Survival rates were significantly better
n the best quartile (Q1) compared with the worst quartile
Q4) for both LVIDd and EF. Survival rates in the
ntermediate quartiles (Q2 and Q3) were similar and virtu-
lly the same as in the overall population.
Mortality and M  M outcomes at the end of the trial
mean follow-up of 23 months) in the best (Q1) compared
ith the worst (Q4) quartile for LVIDd and EF are shown
n Table 1. The combined LVIDd and EF groups (LVIDd
EF) represent the subgroup of patients in Q1 or Q4 for
oth LVIDd and EF. The RR for Q1 versus Q4 on either
ortality or M  M was highly significantly reduced. For
VIDd or EF, the RR approached 0.5, whereas combining
VIDd and EF identified subgroups in which the risk for
atients with the least remodeled ventricles (Q1) was nearly
0% lower than that for the group with the greatest
emodeled ventricles (Q4). Tests for homogeneity of high/
ow odds ratios for LVIDd across high/low categories of EF
ere not significant for either mortality (p 0.334) or M
(p  0.456), indicating consistency of high/low values of
VIDd in predicting outcome risk, regardless of high/low
alues of EF.
Changes over time in LVIDd and EF in the four
Table 1. Outcomes by Baseline Quartiles
Q1
n (%)
LVIDd
Mortality 153 (13.2)
M  M 245 (21.1)
EF
Mortality 202 (13.9)
M  M 329 (22.6)
LVIDd  EF
Mortality 55 (10.7)
M  M 87 (16.9)
*p  0.0001. LVIDd, EF, and combined quartiles at baseline
valsartan and placebo data, using univariate Cox proportiona
CI  confidence interval; EF  ejection fraction; LVIDd
mortality and morbidity; n  number of patients with baseli
RR  risk ratios by Cox regression.uartiles are displayed by treatment in Figure 2. The tbsolute magnitude of LVIDd and EF change was least in
oth treatment groups in Q1 (the quartile with the lowest
aseline LVIDd and the highest baseline EF) and greatest
n Q4 (the quartile with the highest LVIDd and lowest EF).
hese quartile-dependent changes would be anticipated on
he basis of regression to the mean. Nonetheless, in each
uartile, the magnitude of LVIDd decrease and EF increase
t all time points was greater in the valsartan arm than in the
lacebo arm. The one exception was EF in Q2 at month 24.
lacebo-subtracted valsartan effects on LVIDd and EF in
he four quartiles at each time point are summarized in
able 2. Significantly greater decreases in LVIDd and
ncreases in EF were observed in various quartiles in the 4-
nd 12-month data, as well as at the end point with
alsartan compared with placebo.
The effects of valsartan treatment on MM are expressed
s RRs by baseline quartiles of LVIDd and EF (Fig. 3).
alsartan reduced the risk for MM in Q2, Q3, and Q4 for
VIDd by 12%, 20%, and 16%, and for EF by 11%, 15%, and
2%, respectively. Statistically significant RRs in favor of
alsartan were observed in Q3 for LVIDd (p 0.046) and Q4
or EF (p 0.024). The effects of valsartan in Q1 were neutral
or both LVIDd and EF. Although point estimates tended to
emonstrate greater risk reductions with valsartan in the higher
uartiles of LVIDd and EF, the global trends were not
tatistically significant.
ISCUSSION
he present subgroup analysis of Val-HeFT data confirms
hat the degree of LV structural and functional abnormality
s directly related to mortality and morbidity, even when the
nalysis is limited to patients manifesting systolic dysfunc-
ion and ventricular dilation. A low EF is conventionally
iewed as a functional abnormality, and in patients with
table HF, it is usually accompanied by a dilated LV
hamber, evidence viewed as structural remodeling (7). By
ncluding the increased transverse diameter as an entrance
riterion for Val-HeFT, the population was confined to
4
%)
Q1/Q4
RR* 95% CI
27.3) 0.442 0.365–0.534
39.0) 0.485 0.416–0.565
26.4) 0.501 0.420–0.597
40.2) 0.506 0.440–0.582
30.6) 0.319 0.234–0.434
44.9) 0.323 0.253–0.414
mpared with outcomes (mortality and M M) from pooled
rds analysis.
ventricular internal diastolic diameter; M M  combined
ventricular measurements who had an event; Q  quartile;Q
n (
351 (
501 (
325 (
495 (
155 (
227 (
are co
l haza
 left
ne lefthose patients with structural remodeling.
c
a
d
w
q
v
t
M
p
f
F
a
b
a .
T
L
E
*
2025JACC Vol. 43, No. 11, 2004 Wong et al.
June 2, 2004:2022–7 Stratification of LV Remodeling and OutcomesThe aims of the retrospective stratification of the echo-
ardiographic data were to differentiate those HF subgroups
t higher risk of mortality and morbidity and to assess any
ifferential responses to therapy. The study showed that
hen baseline LVIDd and EF were grouped according to
uartiles of severity, patients with the most severely dilated
igure 2. Response to treatment by baseline quartiles. Inter-treatment chan
nd ejection fraction (EF) at months 4, 12, and 24 and the end point are l
ars  valsartan. Asterisks indicate significant placebo-subtracted chan
cross-quartile treatment differences at each time point are not significant
able 2. Placebo-Subtracted Changes From Baseline by Quartile
Month 4 Month
V-P n V-P
VIDd (cm)
Q1 0.10* 520 0.02
Q2 0.06 527 0.03
Q3 0.06 636 0.08*
Q4 0.06 559 0.11*
F (%)
Q1 0.21 659 0.87
Q2 0.78 516 1.33*
Q3 1.00* 511 1.66*
Q4 1.07* 535 1.26*
The letter “n” represents the lower sample size for either valsartan or placebo. Values
P  placebo; V  valsartan; V-P  placebo-subtracted changes from baseline, based on leentricles and depressed systolic function, irrespective of
reatment, were at the greatest risk of mortality and M 
. The finding that both LVIDd and EF were powerful
redictors of outcome suggests that they are both markers
or the severity of the remodeling process.
In Val-HeFT, valsartan compared with placebo exerted a
om baseline quartiles of left ventricular internal diastolic diameter (LVIDd)
quares mean values by analysis of covariance. Open bars  placebo; solid
rom baseline, based on least-square mean values (p  0.05). Global,
Month 24 End Point
n V-P n V-P n
466 0.05 232 0.05 528
468 0.07 229 0.09* 537
556 0.00 293 0.05 649
467 0.11 220 0.09 574
588 0.83 283 0.20 667
449 0.16 225 0.58 527
456 1.04 229 1.40* 521
454 1.19 223 1.12* 542
an asterisk and in bold are for p  0.05. Across-quartile changes are not significant.ges fr
east-s
ges fs
12
with
ast-square mean values by analysis of co-variance; other abbreviations as in Table 1.
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Stratification of LV Remodeling and Outcomes June 2, 2004:2022–7avorable effect on LVIDd and EF in the overall population.
etween 12 and 24 months, when changes reached a
lateau, the absolute maximal mean decrease with valsartan
n LVIDd was0.20 cm, and the maximal mean increase in
F was 4.5% (results not shown for month 18). The
orresponding placebo-subtracted changes were 0.10 cm
nd 1.28%, respectively, which met detectable thresholds
or treatment differences (5). Therefore, small changes were
tatistically significant and physiologically meaningful given
he overall clinical outcome (4). As the anti-remodeling
ffect of valsartan in subgroups based on background ther-
py appeared to correlate with outcomes (4), we hypothe-
ized that the magnitude of effect of valsartan on LVIDd
nd EF would be dependent on the baseline severity of
emodeling, and that outcomes would correspond to the
agnitude of reversal in remodeling.
Analysis of changes from baseline in LVIDd and EF can
e influenced by regression to the mean, and when baseline
alues are truncated by cut-points, subsequent changes will
end to drift toward more normal values. With entry criteria
et at abnormal levels for all quartile subgroups, all changes
ill tend to go in the same direction toward normal, with
he largest changes occurring in the subgroup furthest from
ormal. This appeared to occur; nonetheless, the decrease in
VIDd and increase in EF recorded in the valsartan arm
ended to be greater than in the placebo arm in all quartiles
nd for virtually all time periods (Fig. 2). Although the
bsolute changes were largest in Q3 and Q4, the placebo-
ubtracted changes were similar to the mean changes in the
verall population, but the smaller sample size in each
uartile restricted statistical power (Table 2).
Because the peak effect of valsartan on LVIDd and EF is
elayed, we conjecture that the mechanism operates by
igure 3. Risk by baseline quartiles—effect of valsartan (V) on the combin
s percentage of events, risk ratios, and 95% confidence intervals, calcul
cross-quartile change. EF  ejection fraction; LVIDd  left ventricularlocking tissue angiotensin II, which directly affects LV ltructure by known mitogenic actions (8–10). The finding
hat the more dysfunctional and dilated LVs were associated
ith greater reversal of remodeling and a greater risk
eduction seemed consistent with evidence showing that the
elease of angiotensin II is mediated through stretch of
arcomeres (11,12). However, changes in LVIDd and EF
ere quartile-dependent (Fig. 2), whereas placebo-
ubtracted changes tended to be similar across quartiles
Table 2). Therefore, the angiotensin II-blocking effects of
alsartan remain inferential in explaining the results of this
tudy.
The ideal surrogate for predicting prognosis and for
esting treatment efficacy must have, in addition to a
tatistical relationship, a direct pathophysiologic pathway to
he outcome. A change in the surrogate should result in a
roportional change in outcome (13,14). The treatment
ffects on the outcome, therefore, must be mediated through
he surrogate and not by another causal pathway (15).
al-HeFT, which included serial echocardiograms in all
atients randomized, confirmed the relationship between
ttenuation or reversal of remodeling and clinical benefit
5). A preliminary report also revealed that changes in EF
ver time were associated with corresponding changes in
ortality and morbidity risks (16). In the current study,
aseline LVIDd and EF were found to be strong predictors
f mortality and morbidity, and in combination, an even
tronger prognosticator. From the Studies Of Left Ventric-
lar Dysfunction (SOLVD) data, patients grouped by
edian values for LV mass and EF showed a two- to
hree-fold increase in mortality for those with EF less than
he median combined with LV mass greater than the
edian, as compared with patients with EF above and LV
ass below the median (17). The greater predictability is
d point. Valsartan is compared with placebo (P) for M  M, summarized
sing Cox regression analysis. The p values on the right are for global,
al diastolic diameter.ed en
ated uikely due to both structure and function being indepen-
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June 2, 2004:2022–7 Stratification of LV Remodeling and Outcomesently informative rather than interactive, as the testing of
al-HeFT data for the relationship between LVIDd and
F found that LVIDd consistently predicted the risk of
ortality and M  M, regardless of EF values. The basis
or both structure and function as surrogates lies within the
oncept of remodeling, which is thought to express neuro-
ormonal overcompensation to cardiac injury, and mani-
ested as changes in LV size, shape, and function. This
onstruct is the underpinning for regression of LV remod-
ling that has emerged as a prime surrogate, based on
xperimental and clinical experience (18).
Substudies from ACE inhibitor (19,20) and BB trials
21) showed that treatment improved EF and attenuated or
ecreased ventricular volumes and was associated with a
urvival benefit reported across the whole study population
22,23). The anti-remodeling and clinical benefit attained in
hese studies and the Val-HeFT trials (4,5) have raised the
rospect of tracking EF and cardiac dimensions to deter-
ine efficacy of treatment (18,24). The present study
upports the supposition and further suggests that severity
f remodeling can predetermine which patients are most
ikely to derive benefit.
Mortality was not significantly reduced by valsartan in the
verall population, but treatment was associated with a
ignificant 13.2% reduction in the combined end point of
ortality and morbidity. Was the morbidity benefit influ-
nced by the severity of baseline remodeling? The data are
uggestive but not definitive. A mortality/morbidity advan-
age with valsartan therapy was not observed in the best
uartile (Q1) of LVIDd and EF (Fig. 3). The favorable
ffects of valsartan on outcomes and LV structure and
unction appeared to be greatest in the quartiles with the
idest LVIDd and lowest EF.
onclusions. Val-HeFT has confirmed that stratification
f baseline LVIDd and EF can identify those patients with
F who are most likely to have a fatal or nonfatal event.
hose patients with LVIDd 7.5 cm and EF 22% are at
he highest risk and, at the same time, appear to gain the
ost improvement in structure and function in response to
alsartan. Although all subgroups seemed to respond with
ome reversal of remodeling, the clinical benefit with val-
artan was greatest for those with the more severely dilated
nd dysfunctional ventricles.
eprint requests and correspondence: Dr. Maylene Wong,
eterans Affairs Greater Los Angeles Healthcare System, 11301
ilshire Boulevard, 500/6641, Los Angeles, California 90073.
-mail: maylene.wong@med.va.gov.
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